Impact News +++ If You Invested $1000 In Teradyne Stock 15 Years Ago, You Would Have This Much Today - Benzinga (Benzinga) +++ TERADYNE Aktie +4,56%

REGENERON Aktie

>REGENERON Aktienkurs

660.7 EUR -0.1% (TradegateBSX)

Ask: 667.4 EUR / 90 Stück

Bid: 664.5 EUR / 90 Stück

Tagesumsatz: 225 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: +13,3%

1 Monat: +20,5%

3 Monate: +9,9%

6 Monate: +5,2%

1 Jahr: +39,1%

laufendes Jahr: -0,5%

>REGENERON Aktie

Profil:

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..

Insiderhandel:

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>REGENERON Peer Group

Gesundheit, Antikörper- Behandlung, Augenmedizin/ Sehhilfen, Rheuma- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege
>Alle Branchen..

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

03.08.26 - 10:48	Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN (PR Newswire)
	LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

03.08.26 - 10:48	REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the......

01.08.26 - 17:12	July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.26 - 20:36	Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure - HBSS (PR Newswire)
	SAN FRANCISCO, July 31, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......

31.07.26 - 13:06	Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation (GlobeNewswire EN)
	Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation...

31.07.26 - 03:12	Regeneron (REGN) Q2 2026 Earnings Call Transcript (Fool)
	Revenue surged 17% as Dupixent and EYLEA HD posted record sales....

30.07.26 - 20:30	Regeneron expects EYLEA HD demand growth in the low to mid-teens in Q3–Q4 2026 amid prefilled syringe push (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 18:15	Regeneron (REGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
	While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....

30.07.26 - 17:21	REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 (PR Newswire)
	Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly faced heightened risk of......

30.07.26 - 16:30	Regeneron Pharmaceuticals declares $0.94 dividend (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 14:12	Regeneron übertrifft Erwartungen deutlich: Aktie legt vorbörslich zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 13:24	Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q2 (AFX)
	WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) revealed a profit for second quarter that Drops, from the same period last yearThe company's earnings totaled $1.296 billion, or $12.23 ......

30.07.26 - 13:18	Regeneron rises after strong Q2 beat powered by high-dose Eylea (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 12:39	Regeneron Pharmaceuticals beats top-line and bottom-line estimates; updates FY26 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 12:33	Regeneron Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire EN)
	TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update....

29.07.26 - 19:51	REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman (PR Newswire)
	SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......

29.07.26 - 16:33	Regeneron Pharmaceuticals Q2 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.26 - 16:12	REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm (PR Newswire)
	Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout. NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in......

28.07.26 - 17:30	Can These 5 Biotech Stocks Beat Wall Street′s Q2 Estimates? (Zacks)
	Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results....

28.07.26 - 16:18	Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure - HBSS (PR Newswire)
	SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN) faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Eine gute Doktrin nützt nichts bei einem schlechten Charakter. - Sprichwort Italien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram